Long-term outcomes following CAR T cell therapy: What we know so far

Chimeric antigen receptors (CAR) T cells are a well-known treatment for patients with relapsed/refractory multiple myeloma. This review summarizes long-term follow-up data on efficacy and toxicities from patients treated with CAR-T cells targeting CD19 or B cell maturation antigen (BCMA). It also looks at the factors associated with long-term remissions and discusses ongoing investigational strategies designed to improve the length of remission following CAR T-cell therapy.